Advanced Medical Isotope Corporation (trading symbol QB:ADMD)
1021 N. Kellogg St. Kennewick, Washington 99336 US
T: 509.736.4000 F: 509.736.4007 E:


Latest News

Advanced Medical Isotope CEO Releases Shareholder Letter Outlining New Streamlined Path to FDA Submission

(Tue, 14, Feb 2017) >> read more


Advanced Medical Isotope CEO Issues Letter to Shareholders Issues Full Status Update, Planned FDA Submission Pathway and Business Plan for 2017 and Beyond

(Wed, 11, Jan 2017) >> read more


Advanced Medical Isotope announced today that Dr. Michael Korenko, Ph. D., who formerly served as an advisor to the Board, was named as AMI's interim President and Chief Executive Officer, replacing James Katzaroff.

(Tue, 20, Dec 2016) >> read more


Advanced Medical Isotope announced today that it has been awarded in the Superior Court of the State of Washington in and for Benton County, a total judgment of $527,875.74 USD. 
(Fri, 2, Dec 2016) >> read more


 Click here for more news and updates

Social Media

Future Isotope Projects.

Creating Hope through the use of Medical Isotopes.

In-depth insight into our company and the exciting business of the ever advancing world of medical isotope technology. The video features many of our current Management team as well as the inclusion of Dr. Barry Pressman, Chairman - Medical Advisory Board.

Processing of Molydenum 99

One of AMIC's future goals is to produce the medical imaging isotope Technetium-99m. This critical imaging isotope is created from another commonly known isotope Molybdenum-99 (Mo-99).

Nuclear Fission is used to produce the radioactive substance, Technetium-99m from Molydenum-99. Technetium-99m is employed in more than 16 million nuclear imaging procedures per-year in the US alone.


Vital procedures ranging from sentinel node biopsies in cancer surgery to bone scans and cardiac stress tests are threatened by current shortages of Mo-99. With aging production reactors closing or experiencing problems, the US must import 100% of it’s Mo-99. AMIC, with its partners, is developing a way to produce Mo-99 and other critical radioisotopes domestically using an efficient compact accelerator instead of a nuclear reactor. This concept will save a significant amount of money and time in production. AMIC is moving this project forward and will be announcing progress as developments are confirmed. 


Molydenum-99 • Supply and Demand issues

"Critical shortage of Molybdenum-99 and its derivative, Technetium-99m, the most commonly used medical radioisotope in the world – used in 50,000 diagnostic medical procedures in the US every day"
"Critical shortage of Molybdenum-99 and its derivative, Technetium-99m, the most commonly used medical radioisotope in the world – used in 50,000 diagnostic medical procedures in the US every day"

Medical diagnostic imaging techniques using Technetium-99m account for roughly 80% of all nuclear medicine procedures. This represents over 30 million examinations worldwide every year.


Disruptions in the supply chain of these medical isotopes – which have half-lives of 66 hours for molybedenum-99 (99Mo) and 6 hours for its daughter isotope, technetium-99m (99mTc), and thus must be produced continually – can lead to cancellations or delays in important medical testing services.


Unfortunately, supply and reliability has declined over the past decade due to unexpected or extended shutdowns at the few aging 99Mo producing research reactor and processing facilities. These shutdowns have created global supply shortages.


Although there is currently no commercial production of Mo-99 in the United States, this was not always the case. Prior to 1989, Cintichem, Inc. produced Mo-99 for the U.S. market using a 5 MWt (megawatt thermal) research reactor located in Tuxedo, New York. This reactor was shut down when tritium contamination of surface waters adjacent to the reactor site was confirmed. A decision to decommission the reactor was subsequently made after a risk-benefit study carried out by Cintichem’s parent company, Hoffman- LaRoche, determined that its continued operation was not justified. Cintichem offered to arrange a long-term supply agreement with the other North American supplier, the Canadian company Nordion (later MDS Nordion), to supply Mo-99 to U.S. technetium generator manufacturers (Amersham [now GE Healthcare], Mallinckrodt, and DuPont(*1).


(*1) Of these three, only Mallinckrodt continues to supply technetium generators to the U.S. market.